These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 3926352)

  • 1. The treatment of central precocious puberty using an intranasal LHRH analogue (buserelin).
    Stanhope R; Adams J; Brook CG
    Clin Endocrinol (Oxf); 1985 Jun; 22(6):795-806. PubMed ID: 3926352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal and subcutaneous treatment of central precocious puberty in both sexes with a long-acting analog of luteinizing hormone-releasing hormone.
    Luder AS; Holland FJ; Costigan DC; Jenner MR; Wielgosz G; Fazekas AT
    J Clin Endocrinol Metab; 1984 Jun; 58(6):966-72. PubMed ID: 6427266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of central precocious puberty with an intranasal analogue of GnRH (Buserelin).
    Bourguignon JP; Van Vliet G; Vandeweghe M; Malvaux P; Vanderschueren-Lodeweyckx M; Craen M; Du Caju MV; Ernould C
    Eur J Pediatr; 1987 Nov; 146(6):555-60. PubMed ID: 3123239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term treatment of central precocious puberty with an intranasal LHRH analogue: control of pituitary function by urinary gonadotropins.
    Rime JL; Zumsteg U; Blumberg A; Hadziselimovic F; Girard J; Zurbrügg RP
    Eur J Pediatr; 1988 Apr; 147(3):263-9. PubMed ID: 3134243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversible inhibition of central precocious puberty with a long acting GnRH analogue.
    Ward PS; Ward I; McNinch AW; Savage DC
    Arch Dis Child; 1985 Sep; 60(9):872-4. PubMed ID: 3931565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Luteinizing hormone-releasing hormone analogue (Buserelin) treatment for central precocious puberty: a multi-centre trial.
    Werther GA; Warne GL; Ennis G; Gold H; Silink M; Cowell CT; Quigley C; Howard N; Antony G; Byrne GC
    J Paediatr Child Health; 1990 Feb; 26(1):4-8. PubMed ID: 2109996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LH-RH agonistic analog (buserelin) treatment of precocious puberty: collaborative study in Japan.
    Suwa S; Hibi I; Kato K; Nakazima H
    Acta Paediatr Jpn; 1988; 30 Suppl():176-84. PubMed ID: 3146872
    [No Abstract]   [Full Text] [Related]  

  • 8. Final height in sexually precocious girls after therapy with an intranasal analogue of gonadotrophin-releasing hormone (buserelin).
    Stasiowska B; Vannelli S; Benso L
    Horm Res; 1994; 42(3):81-5. PubMed ID: 7995616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up and final height in girls with central precocious puberty treated with luteinizing hormone-releasing hormone analogue nasal spray.
    Cacciari E; Cassio A; Balsamo A; Colli C; Cicognani A; Pirazzoli P; Tani G; Brondelli L; Mandini M; Bovicelli L
    Arch Pediatr Adolesc Med; 1994 Nov; 148(11):1194-9. PubMed ID: 7921123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gonadotrophin responses to GnRH in precocious puberty treated with GnRH analogue.
    Donaldson MD; Stanhope R; Lee TJ; Price DA; Brook CG; Savage DC
    Clin Endocrinol (Oxf); 1984 Nov; 21(5):499-503. PubMed ID: 6437705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term results of GnRH analogue (Buserelin) treatment in girls with central precocious puberty.
    Brauner R; Thibaud E; Bischof P; Sizonenko PC; Rappaport R
    Acta Paediatr Scand; 1985 Nov; 74(6):945-9. PubMed ID: 3937430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of precocious puberty using an intranasal luteinizing hormone-releasing hormone analogue: Buserelin.
    Low LC; Wang C; Cheung PT; Chan FL
    Aust Paediatr J; 1989 Oct; 25(5):274-8. PubMed ID: 2511831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variations in pituitary-gonadal suppression during intranasal buserelin and intramuscular depot-triptorelin therapy for central precocious puberty. Belgian Study Group for Pediatric Endocrinology.
    Heinrichs C; Craen M; Vanderschueren-Lodeweyckx M; Malvaux P; Fawe L; Bourguignon JP
    Acta Paediatr; 1994 Jun; 83(6):627-33. PubMed ID: 7919761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Subcutaneous and intranasal use of a LH-RH analog in the treatment of girls with central precocious puberty].
    Fideleff HL; Boquete HR; Azaretzky M; Damilano S; Cagide AL; Levalle O
    Medicina (B Aires); 1989; 49(6):567-72. PubMed ID: 2518644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of central precocious puberty with an LHRH agonist (Buserelin): effect on growth and bone maturation after three years of treatment.
    Rappaport R; Fontoura M; Brauner R
    Horm Res; 1987; 28(2-4):149-54. PubMed ID: 2969858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long term treatment of male and female precocious puberty by periodic administration of a long-acting preparation of D-Trp6-luteinizing hormone-releasing hormone microcapsules.
    Roger M; Chaussain JL; Berlier P; Bost M; Canlorbe P; Colle M; Francois R; Garandeau P; Lahlou N; Morel Y
    J Clin Endocrinol Metab; 1986 Apr; 62(4):670-7. PubMed ID: 2936759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Short-term comparison of the treatment of precocious puberty with 2 different LHRH antagonists (buserelin and long-acting triptorelin). An endocrinologic and echographic study].
    Cicognani A; Cacciari E; Balsamo A; Cassio A; Papasodero A; Bellizzi M; Guacci P; Zappulla F
    Pediatr Med Chir; 1994; 16(1):43-8. PubMed ID: 8029088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation and significance of the degree of pituitary-gonadal inhibition during intranasal administration of buserelin.
    Bourguignon JP; Heinrichs C; Van Vliet G; Vandeweghe M; Vanderschueren-Lodeweyckx M; Malvaux P; Du Caju M; Craen M; Lambrechts L; Delire M
    Acta Endocrinol (Copenh); 1987 Dec; 116(4):519-25. PubMed ID: 3122484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of true precocious puberty with a potent luteinizing hormone-releasing factor agonist: effect on growth, sexual maturation, pelvic sonography, and the hypothalamic-pituitary-gonadal axis.
    Styne DM; Harris DA; Egli CA; Conte FA; Kaplan SL; Rivier J; Vale W; Grumbach MM
    J Clin Endocrinol Metab; 1985 Jul; 61(1):142-51. PubMed ID: 3923027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of puberty in girls with short-acting intranasal versus subcutaneous depot GnRH agonist.
    Tuvemo T; Gustafsson J; Proos LA;
    Horm Res; 2002; 57(1-2):27-31. PubMed ID: 12006716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.